Description

Rutinib 5mg Tablet (Ruxolitinib) – Uses, Side Effects, Dosage & Price in Pakistan

Rutinib 5mg Tablet contains Ruxolitinib, a prescription medicine belonging to the Janus kinase (JAK) inhibitor group. It is used for certain blood and immune-system conditions, including specific types of myelofibrosis, polycythemia vera, and selected cases of graft-versus-host disease.

Rutinib 5mg Tablet requires medical supervision because ruxolitinib can affect blood-cell counts and may increase the risk of infections and other complications. Your doctor may perform regular blood tests and adjust the dose according to your condition and treatment response.

Rutinib 5mg Tablet (Ruxolitinib) Uses

Rutinib 5mg Tablet may be prescribed for intermediate- or high-risk myelofibrosis in adults, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. Ruxolitinib is also used for adults with polycythemia vera who have had an inadequate response to or cannot tolerate hydroxyurea.

Ruxolitinib tablets are also indicated for steroid-refractory acute graft-versus-host disease in adults and children aged 12 years and older. They may also be used for chronic graft-versus-host disease after failure of one or two lines of systemic treatment in adults and pediatric patients aged 12 years and older.

The exact reason for prescribing Rutinib depends on the patient’s diagnosis, blood counts, previous treatments, age, and overall health.

Ruxolitinib for Myelofibrosis

Myelofibrosis is a serious blood disorder that can interfere with normal blood-cell production in the bone marrow. It may cause symptoms such as fatigue, weakness, fever, night sweats, weight loss, and abdominal discomfort associated with an enlarged spleen.

Ruxolitinib inhibits JAK1 and JAK2 signaling. These pathways are involved in processes that contribute to abnormal blood-cell production and inflammatory signaling. By reducing this signaling, ruxolitinib can help manage certain manifestations of myelofibrosis.

The dose is not selected simply according to the tablet strength. For myelofibrosis, the recommended starting dose is determined largely by the patient’s baseline platelet count.

Ruxolitinib for Polycythemia Vera

Polycythemia vera is a blood disorder in which the body produces too many blood cells, particularly red blood cells. This can increase blood thickness and the risk of complications.

Ruxolitinib is indicated for adults with polycythemia vera who have had an inadequate response to hydroxyurea or cannot tolerate it. The recommended starting dose in the current U.S. prescribing information is 10mg twice daily, although treatment can be modified according to blood counts, safety, and response.

A 5mg tablet may therefore be used as part of an individualized dosing regimen, but having a 5mg tablet does not mean every patient should take 5mg twice daily.

Rutinib 5mg Tablet Dosage

The appropriate Rutinib dosage depends on the condition being treated and individual patient factors.

For myelofibrosis, the current prescribing information recommends starting doses according to platelet count:

• Platelets above 200 × 10⁹/L: 20mg twice daily
• Platelets from 100 × 10⁹/L to 200 × 10⁹/L: 15mg twice daily
• Platelets from 50 × 10⁹/L to below 100 × 10⁹/L: 5mg twice daily

For steroid-refractory acute graft-versus-host disease, the recommended starting dose is 5mg twice daily, with possible adjustment according to blood-count response and the treating physician’s assessment.

Therefore, patients should not select the dose based only on the strength printed on the medicine pack. The prescribing doctor should determine the appropriate regimen.

How to Take Rutinib 5mg Tablet

Rutinib 5mg Tablet is taken orally according to the prescription. Ruxolitinib tablets can generally be taken with or without food.

Take the medicine at the same times each day and follow the exact schedule provided by your healthcare professional. Do not take extra tablets to make up for a missed dose unless your doctor specifically instructs you to do so.

Before starting treatment, a complete blood count should be performed. During treatment, CBC monitoring is recommended every 2 to 4 weeks until the dose is stable and then as clinically indicated. Lipid levels may also be assessed approximately 8 to 12 weeks after treatment begins.

How Rutinib 5mg Tablet (Ruxolitinib) Works

Rutinib contains Ruxolitinib, which works by inhibiting the JAK1 and JAK2 enzymes. These enzymes are involved in signaling pathways used by various cytokines and growth factors.

Abnormal JAK signaling plays an important role in several myeloproliferative disorders. By inhibiting JAK activity, ruxolitinib reduces certain abnormal signaling processes involved in these diseases.

The response to treatment can differ from one patient to another, so regular clinical assessments and laboratory tests are important during therapy.

Rutinib 5mg Tablet Side Effects

Rutinib 5mg Tablet may cause side effects, although not everyone experiences them. The type and severity of adverse effects can depend on the condition being treated, dosage, treatment duration, and the patient’s health.

Commonly reported adverse reactions with ruxolitinib include:

• Anemia
• Thrombocytopenia
• Neutropenia
• Bruising
• Dizziness
• Headache
• Diarrhea
• Fatigue
• Infections

In myelofibrosis and polycythemia vera, anemia and thrombocytopenia are among the most common blood-related adverse reactions.

Serious Side Effects of Rutinib

Some adverse effects require prompt medical attention.

Blood Cell Changes

Ruxolitinib can reduce platelet, red blood cell, and neutrophil counts. This can result in thrombocytopenia, anemia, or neutropenia.

Your doctor may reduce the dose, temporarily interrupt treatment, or use supportive measures when clinically appropriate. Regular CBC testing is therefore an important part of treatment.

Infections

Ruxolitinib can increase the risk of serious infections. Before treatment, healthcare professionals may review a patient’s history of infections, including tuberculosis, herpes simplex, herpes zoster, and hepatitis B.

Patients should report symptoms such as persistent fever, chills, cough, unusual weakness, or other signs of infection promptly. Serious active infections should be appropriately managed before treatment begins.

Blood Clots and Cardiovascular Problems

The prescribing information contains warnings about thrombosis and major adverse cardiovascular events. Patients should seek urgent medical care if they develop symptoms that may indicate a blood clot or serious cardiovascular event.

Skin Cancer

Non-melanoma skin cancers have been reported during treatment with ruxolitinib. Periodic skin examinations may therefore be recommended by the healthcare professional.

Rutinib 5mg Tablet Precautions

Before taking Rutinib, inform your doctor about your complete medical history and all medicines you use.

Tell your healthcare professional if you have:

• A history of recurrent or serious infections
• Tuberculosis or previous exposure to tuberculosis
• Hepatitis B or other significant infections
• Kidney problems
• Liver problems
• Blood-count abnormalities
• Cardiovascular risk factors
• A history of skin cancer

Blood tests are required before treatment and during therapy to monitor blood-cell counts. Ruxolitinib may also affect lipid levels, which may require monitoring after treatment starts.

Do not stop Rutinib suddenly without medical advice. Interruption or discontinuation of ruxolitinib can lead to worsening of symptoms associated with the underlying condition.

Rutinib 5mg Tablet Drug Interactions

Ruxolitinib can interact with medicines that affect its metabolism. Strong CYP3A4 inhibitors may require dose modification, and special precautions apply when ruxolitinib is used with fluconazole.

The current prescribing information advises avoiding fluconazole doses above 200mg together with ruxolitinib and recommends dose reduction with fluconazole doses of 200mg or less, according to the applicable indication.

Always tell your doctor about prescription medicines, over-the-counter medicines, vitamins, and supplements before starting Rutinib.

Rutinib 5mg in Kidney or Liver Problems

Patients with kidney or liver impairment may require a lower starting dose or other treatment adjustments.

The appropriate dose depends on the severity of organ impairment and the condition being treated. Do not adjust Rutinib yourself if you have kidney or liver disease. Your doctor should determine the safest treatment plan.

Who Should Use Rutinib 5mg Tablet?

Rutinib 5mg Tablet should only be used when prescribed for an appropriate medical condition. It is not suitable for treating ordinary weakness, anemia, or other blood-related symptoms without a confirmed diagnosis.

The doctor may consider the patient’s diagnosis, platelet count, CBC results, previous treatment, infection history, kidney and liver function, and other medicines before selecting a dose.

Importantly, 5mg is a tablet strength, not a universal daily dose. Depending on the condition, 5mg may be prescribed twice daily or may be used as part of a dose-adjustment plan.

Rutinib 5mg Tablet Price in Pakistan

The Rutinib 5mg Tablet price in Pakistan may vary depending on the manufacturer, pack size, supplier, availability, import conditions, and pharmacy location. Medicine prices can change, so the current price should be confirmed before ordering.

For the latest availability and Rutinib 5mg Tablet price in Pakistan, customers can contact Impo Medic and confirm the current product details, pack size, and purchasing information.

How to Buy Rutinib 5mg Tablet in Pakistan

Rutinib 5mg Tablet is a prescription medicine and should be purchased from a reliable pharmacy or authorized medicine supplier. Before purchasing, check the medicine name, strength, packaging, batch information, expiry date, and storage condition.

Impo Medic can help customers check medicine availability and purchasing information in Pakistan. Because Ruxolitinib requires medical monitoring, patients should use Rutinib only according to a qualified healthcare professional’s prescription.

Frequently Asked Questions About Rutinib 5mg Tablet (Ruxolitinib)

What is Rutinib 5mg Tablet (Ruxolitinib) used for?

Rutinib 5mg Tablet contains Ruxolitinib and may be prescribed for certain types of myelofibrosis, polycythemia vera, and specific cases of acute or chronic graft-versus-host disease.

Is Rutinib 5mg used for myelofibrosis?

Yes. Ruxolitinib is indicated for intermediate- or high-risk myelofibrosis in adults, including primary myelofibrosis and myelofibrosis occurring after polycythemia vera or essential thrombocythemia.

What is the usual Rutinib 5mg dosage?

The dose depends on the medical condition and patient factors. For myelofibrosis, 5mg twice daily is the recommended starting dose when the baseline platelet count is 50 × 10⁹/L to below 100 × 10⁹/L. It is also the recommended starting dose for steroid-refractory acute graft-versus-host disease.

What are the common Rutinib side effects?

Common adverse reactions can include anemia, thrombocytopenia, bruising, dizziness, headache, diarrhea, and infections.

Does Rutinib increase the risk of infection?

Yes. Ruxolitinib can increase the risk of infections, including serious infections. Patients should report signs of infection to their healthcare professional promptly.

Can I stop Rutinib 5mg suddenly?

Do not stop Rutinib without consulting your doctor. Symptoms may worsen following interruption or discontinuation of ruxolitinib, and your healthcare professional can determine the appropriate treatment plan.

Is Rutinib 5mg available in Pakistan?

Availability can vary between suppliers and pharmacies. Contact Impo Medic or a licensed pharmacy to confirm current availability, pack details, and price.

Final Thoughts on Rutinib 5mg Tablet (Ruxolitinib)

Rutinib 5mg Tablet contains Ruxolitinib, a JAK1 and JAK2 inhibitor used for specific blood and immune-related conditions. Its approved uses include certain cases of myelofibrosis, polycythemia vera, and graft-versus-host disease.

The appropriate dose depends on the patient’s diagnosis, blood counts, treatment response, and other clinical factors. Because ruxolitinib can cause changes in blood-cell counts and increase infection risk, regular medical monitoring is important.

For medicine availability and purchasing information in Pakistan, Impo Medic can help customers check current product details. Always use Rutinib according to your doctor’s prescription and do not change the dose without medical advice.